Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase NA 3Phase 1 3Phase 2/3 2Phase 1/2 1

Status

Unknown 5Completed 4Not yet recruiting 3Withdrawn 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Inflammatory Breast Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Oxaliplatin 5Leucovorin 5Fluorouracil 5Gemcitabine 4pirarubicin 2liposomal doxorubicin 2Surgical Procedures, Operative 2Radiation 2Paclitaxel 2Neoadjuvant Therapy 2Folfox protocol 2Capecitabine 22-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 2vocimagene amiretrorepvec 1taxane 1sulindac sulfone 1remdesivir 1pembrolizumab 1nimotuzumab 1methylnaltrexone 1lenvatinib 1irinotecan sucrosofate 1carbon-11 acetate 1bavituximab 1alovudine 1aflibercept 1Thyroxine 1Therapeutics 1Temozolomide 1Taxes 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Withdrawn × Neoadjuvant Therapy × Clear all
NCT00397761 2021-02-17

Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) in Treating Women Undergoing Surgery for Stage II or Stage III Breast Cancer

Medstar Health Research Institute

Phase 2/3 Withdrawn
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT02584556 2019-06-04

Adjuvant Transcatheter Arterial Chemoembolization Versus Adjuvant Systemic Chemotherapy for Hepatocellular Carcinoma

Guangxi Medical University

Phase 2/3 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡